• Lopinavir (ABT-378): Optimizing HIV Protease and Antiviral A

  2026-07-08

  Lopinavir (ABT-378) is a benchmark HIV protease inhibitor, offering unmatched potency against both wild-type and mutant strains—even in serum-rich environments. Its cross-domain antiviral activity, robust pharmacokinetics, and resistance resilience make it indispensable for both HIV and emerging coronavirus research.

• Heparin Sodium in Next-Generation Anticoagulant Research Mod

  2026-07-07

  Explore the advanced role of Heparin sodium as a glycosaminoglycan anticoagulant in preclinical research. This article delivers unique insights into mechanistic innovations, protocol guidance, and new biological intersections that set it apart from standard product literature.

• DiscoveryProbe™ Metabolism-related Compound Library: Technic

  2026-07-07

  The DiscoveryProbe™ Metabolism-related Compound Library enables reliable, high-throughput screening of 493 metabolism-focused small molecules for in vitro and ex vivo research. This resource addresses the need for rigorously validated, cell-permeable compounds targeting metabolic enzymes and pathways. It is not intended for clinical, in vivo, or diagnostic applications.

• Verapamil HCl: L-type Calcium Channel Blocker in Translation

  2026-07-06

  Verapamil HCl is an L-type calcium channel blocker with validated roles in modulating cellular excitability, apoptosis, and inflammation. Its Txnip-targeted effects underpin new osteoporosis mechanisms and offer robust tools for myeloma and arthritis models. Benchmark data confirm its solubility, bioactivity, and translational potential.

• Fluo-4 AM (SKU B8807): Reliable Calcium Imaging for Cell Ass

  2026-07-06

  This article delivers a scenario-driven, evidence-based guide to optimizing intracellular calcium concentration measurement with Fluo-4 AM (SKU B8807). It addresses real laboratory challenges in viability, proliferation, and cytotoxicity assays, offering practical protocol insights and data-backed comparisons. Researchers will learn why APExBIO’s Fluo-4 AM is a leading choice for reproducibility and sensitivity in calcium signaling research.

• BX795: Precision PDK1 Inhibition for Advanced Cancer Researc

  2026-07-05

  This article delivers strategic guidance for translational researchers on leveraging BX795, an ATP-competitive PDK1 inhibitor, to dissect cancer and innate immune signaling. Drawing on the latest in vitro viability metrics and mechanistic studies, it advances the conversation beyond standard product pages, providing protocol parameters, competitive landscape analysis, and a forward-looking translational outlook.

• Tacalcitol Monohydrate: Molecular Precision in Dermatology a

  2026-07-04

  Explore the advanced mechanisms of Tacalcitol monohydrate, a synthetic analog of vitamin D3, in regulating gene expression, enhancing cancer therapies, and offering next-generation solutions for dermatology. Learn how APExBIO's reagent empowers researchers with unique, evidence-backed applications.

• Paroxetine Mesylate: Advanced SSRI Workflows in Oncology Res

  2026-07-03

  Paroxetine Mesylate, a selective serotonin reuptake inhibitor, delivers unique research value by combining potent SERT blockade with multi-kinase inhibition. Its demonstrated anticancer activity in colorectal models and broad experimental versatility offers new opportunities for translational workflows and drug repurposing strategies.

• Cy7 NHS Ester: Practical Guide for Near-Infrared Protein Lab

  2026-07-03

  Cy7 NHS ester is a sulfonated, highly water-soluble near-infrared dye for covalently labeling primary amines in proteins and peptides. It is best suited for workflows requiring sensitive, aqueous conjugation and near-infrared fluorescent imaging, particularly where organic co-solvents would risk biomolecule denaturation. It is not appropriate for targets lacking amines or applications needing long-term dye solution stability.

• CCCP in Mitochondrial Morphology Assays: Applied Protocols &

  2026-07-02

  CCCP (carbonyl cyanide m-chlorophenyl hydrazine) is a benchmark tool for mitochondrial proton gradient disruption, enabling reproducible modeling of metabolic dysfunction and disease. This article distills advanced workflows, practical troubleshooting, and the latest AI-powered innovations for leveraging CCCP in non-invasive mitochondrial research.

• Linezolid and the Evolving Landscape of MDR Research

  2026-07-02

  This thought-leadership article explores the mechanistic, experimental, and translational facets of Linezolid as a model oxazolidinone antimicrobial in multidrug-resistant (MDR) Gram-positive pathogen research, drawing strategic lessons for innovators targeting intractable bacterial infections. It contextualizes recent advances in oxazole-based anti-tubercular agents, underscores the importance of protein synthesis inhibition, and provides actionable guidance for researchers bridging bench to bedside.

• CD40–STING–TRAF2 Axis Drives B Cell Activation in ESCC

  2026-07-01

  This study uncovers how competitive binding between CD40 and STING with TRAF2 activates IRF4-mediated B cell responses within tertiary lymphoid structures in esophageal squamous cell carcinoma. These mechanistic insights advance our understanding of the immunological microenvironment in ESCC and inform future biomarker and therapeutic development.

• LC–MS/MS Reveals GS-441524 Prodrug Conversion Pathways In Vi

  2026-07-01

  This study introduces a novel GS-441524 prodrug (NGP-1) designed for enhanced oral bioavailability and anti-SARS-CoV-2 activity. Using a newly established LC–MS/MS method, the research maps NGP-1's stepwise conversion to the active nucleoside both in vitro and in vivo, providing key insights for antiviral drug development and pharmacokinetic analysis.

• T-5224: Applied Workflows for C-Fos/AP-1 Inhibition in Infla

  2026-06-30

  T-5224 stands out as a selective C-Fos/AP-1 inhibitor, empowering researchers to dissect and modulate inflammatory and osteoclastogenic pathways with remarkable specificity. This article translates recent neuroinflammatory research into actionable experimental protocols and troubleshooting strategies, highlighting how T-5224 from APExBIO accelerates progress in arthritis and pain models.

• Cy3 Goat Anti-Human IgG (H+L) Antibody: Precision in Immunoa

  2026-06-30

  The Cy3 Goat Anti-Human IgG (H+L) Antibody stands out for its robust signal amplification and versatility across immunofluorescence, IHC, flow cytometry, and ELISA workflows. With high specificity and minimal cross-reactivity, it empowers advanced human IgG detection in translational and clinical research.

421 records 10/29 page Previous Next First page 上5页 678910 下5页 Last page